La cadena de opciones muestra datos clave de las opciones de acciones de Indaptus Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Indaptus Therapeutics..

Indaptus Therapeutics (NASDAQ:INDP) Bolsa, Cadena de Opciones

Indaptus Therapeutics

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics Inc

MSC Income Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSIF#NYSE">MSIF</a>) reported quarterly earnings of $0.38 per share. This is a 5.56 percent increase over earnings of $0.36 per share from the same period last year. The company reported $33.23 million in sales this quarter. This is a 2.13 percent decrease over sales of $33.95 million the same period last year.

Earnings

News

MSIF

MSC Income Fund Q1 EPS $0.38 Up From $0.36 YoY, Sales $33.23M Down From $33.95M YoY

Archer Aviation Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) reported first-quarter financial results Monday after the bell. Here&#8217;s a rundown of the <a href="https://www.benzinga.com/pressreleases/25/05/b45359248/archer-announces-first-quarter-results-highlighting-on-track-uae-launch-new-launch-edition-custome">company&#8217;s report</a>.
Q1 Earnings: Archer Aviation, which designs electric vertical take-off and landing (eVTOL) aircraft, reported a first-quarter loss of 17 cents per share, beating analyst <a href="http://benzinga.com/quote/achr/earnings">estimates</a> for a loss of 28 cents per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Archer highlighted the announcement of its first two customers for its Midnight Edition launch in the first quarter and said it plans to deliver its first Midnight aircraft to the UAE in the coming months, with planned deployment slated for later this year.
The company also highlighted a partnership it signed with Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) in the first quarter to build AI for the future of next-generation aviation technologies. The companies plan to work together to develop AI software to improve a range of aviation systems.
Archer said its quarterly spending stayed within the previously guided range. The company ended the period with $1.03 billion in cash and cash equivalents, the highest cash position in company history. 
&#8220;Archer&#8217;s pushing the boundaries of what&#8217;s possible and reshaping the future of aviation for years to come.&nbsp;This quarter, the team made strong progress across our civil and defense efforts as we continue to deepen our strategic partner relationships and prepare for commercialization in the UAE later this year,&#8221; said&nbsp;Adam Goldstein, founder and CEO of Archer.
Archer reported an adjusted EBITDA loss of $109 million in the quarter and guided for a second-quarter adjusted EBITDA loss of $100 million to $120 million.
Archer Aviation executives will further discuss the quarter on a call with investors and analysts at 5 p.m. ET.
ACHR Price Action: <a href="http://benzinga.com/quote/achr" target="_blank" rel="noreferrer noopener">Archer Aviation shares</a> were up 5.29% in Monday&#8217;s after-hours session, trading at $9.56 at the time of publication, per <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45354683/tesla-probably-wont-make-money-on-ride-hailing-for-years-gary-black-says">Tesla Robotaxi Hopes Dashed By Uber, Lyft: No Fast Lane To Profits, Warns Investor Gary Black</a></li>
</ul>
Photo: courtesy of Archer Aviation.

Guidance

After-Hours Center

Movers

ACHR

PLTR

Archer Aviation Reports Smaller-Than-Expected Loss In Q1, Company Says UAE Launch Remains 'On Track' For 2025, Shares Surge

Management

IFBD

Infobird Says On May 7 Xiangyang Wen Was Appointed As CEO

Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) affirms FY2025 Adj EPS guidance from $2.50-$2.80 to $2.50-$2.80 vs $2.65 analyst estimate. Affirms FY2025 sales outlook from $3.30 billion-$3.40 billion to $3.30 billion-$3.40 billion vs $3.34 billion estimate.

ACHC

Acadia Healthcare Co Affirms FY2025 Adj EPS Guidance of $2.50-$2.80 vs $2.65 Est; Affirms FY2025 Sales Guidance of $3.30B-$3.40B vs $3.34B Est

Barclays analyst Adrienne Yih maintains Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) with a Equal-Weight and lowers the price target from $309 to $276.

Price Target

Analyst Ratings

LULU

Barclays Maintains Equal-Weight on Lululemon Athletica, Lowers Price Target to $276

Star Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STHO#NASDAQ">STHO</a>) reported quarterly losses of $(0.57) per share. This is a 84.51 percent increase over losses of $(3.68) per share from the same period last year. The company reported $14.62 million in sales this quarter. This is a 42.51 percent decrease over sales of $25.44 million the same period last year.

STHO

Star Hldgs Q1 EPS $(0.57) Up From $(3.68) YoY, Sales $14.62M Down From $25.44M YoY

- Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) today announced new data from Week 214 of its Phase 2 PaTH Forward Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) continued to provide a durable response in adults with hypoparathyroidism. Results were shared in an oral presentation today by Andrea Palermo, M.D., from the Campus Bio-Medico University (Rome), during ESPE &amp; ESE 2025, the joint congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE).
The PaTH Forward Trial included a 4-week randomized, double-blind, placebo-controlled period followed by an open-label extension period through Week 266. Renal function was assessed by estimated glomerular filtration rate (eGFR). Bone turnover markers C-terminal telopeptide of type 1 collagen (CTx) and procollagen type 1 N-terminal propeptide (P1NP), as well as bone mineral density (BMD) measured by DXA scan, were assessed at baseline and regular intervals through Week 214. Safety assessments included 24-hour urine-calcium and treatment-emergent adverse events (TEAEs). At Week 214, 56 of the original 59 patients enrolled (95%) remained in the open-label extension portion of the trial.
At Week 214, nearly all patients (98%) continued to have normal albumin-adjusted serum calcium levels and 93% remained independent from conventional therapy (defined as taking &lt; 600mg/day of calcium and not taking active vitamin D). Bone turnover markers CTx and P1NP increased from the low end of normal at baseline, peaked by Week 26, then declined and remained stable above baseline levels through Week 214. The data also showed continued improvement in skeletal dynamics, with BMD remaining within age- and sex-matched norms. In addition, at Week 214, most participants (67.8%) had a clinically meaningful (≥ 5&nbsp;mL/min/1.73 m2) increase in eGFR from baseline, with changes in eGFR evident at Week 4.
In the trial, TransCon PTH treatment was generally well-tolerated, with no new safety signals identified. TEAEs were mostly mild or moderate and no serious TEAEs or discontinuations were related to study drug.
"We set out to address the underlying cause of disease and are pleased to see this long-term data reinforcing the safety profile and durability of response in patients treated with TransCon PTH, including sustained normalization of skeletal dynamics and significant and sustained improvements in kidney function," said&nbsp;Aimee Shu,&nbsp;M.D.&nbsp;Executive Vice President of Endocrine &amp; Rare Disease Medical Science and Chief Medical Officer at Ascendis Pharma.

Biotech

General

ASND

Ascendis Pharma Announces New Data From Week 214 Of Its Phase 2 Path Forward Trial Showing That Long-Term Treatment With TransCon PTH Continued To Provide A Durable Response In Adults With Hypoparathyroidism

Buybacks

Axos Financial Reveals $100M Increase To The Existing Stock Repurchase Program

Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 32 percent increase over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $421.00 thousand which missed the analyst consensus estimate of $1.27 million by 66.79 percent. This is a 75.48 percent decrease over sales of $1.72 million the same period last year.

Earnings Misses

Cue Biopharma Q1 EPS $(0.17) Misses $(0.15) Estimate, Sales $421.00K Miss $1.27M Estimate

Jasper Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSPR#NASDAQ">JSPR</a>) reported quarterly losses of $(1.41) per share which missed the analyst consensus estimate of $(1.33) by 6.02 percent. This is a 36.89 percent decrease over losses of $(1.03) per share from the same period last year.

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

Jasper Therapeutics Q1 EPS $(1.41) Misses $(1.33) Estimate

RBOT

Vicarious Surgical Collaborates With UMass Memorial Medical Center To Support Adoption And Utilization Of Its Robotic System Through Perioperative Practices

GoPro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPRO#NASDAQ">GPRO</a>) is looking for Q2 Adj EPS of $(0.11)-$(0.03) vs $(0.12) analyst estimate. sees sales of $135.000 million-$155.000 million vs $124.65 million analyst estimate.

GPRO

GoPro Sees Q2 Adj EPS $(0.11)-$(0.03) vs $(0.12) Est; Sees Sales $135.000M-$155.000M vs $124.65M Est

NuScale Power Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) released its first-quarter results after Monday's closing bell. Here's a look at the key figures <a href="https://www.benzinga.com/pressreleases/25/05/b45359929/nuscale-power-reports-first-quarter-2025-results">from the quarter. </a>
The Details: NuScale Power reported quarterly revenue of $13.4 million, which beat the analyst consensus estimate of $4.26 million. The company said revenues were driven by its FEED Phase 2 project and its Technology License Agreement for the RoPower Doicești power plant.
NuScale ended the first quarter with cash, cash equivalents and short-term investments of $521.4 million.
Read Next: <a href="https://www.benzinga.com/25/05/45354683/tesla-probably-wont-make-money-on-ride-hailing-for-years-gary-black-says?utm_source=articleShare">Tesla Robotaxi Hopes Dashed By Uber, Lyft: No Fast Lane To Profits, Warns Investor Gary Black&nbsp;</a>
Quarterly operating expenses decreased by $2.3 million to $42.3 million, compared to $44.6 million in the prior year&#8217;s quarter. The decrease was primarily driven by lower research and development expenses, partially offset by higher general and administrative expenses as NuScale continued to transition from research and development to commercialization.
&#8220;In the first quarter, NuScale continued to take proactive steps to build on our leadership as the first and only SMR provider to receive NRC design approval,&#8221; said John Hopkins, CEO of NuScale Power.
&#8220;With 12 modules already in the manufacturing process, we further readied our supply chain to ensure we stay on course to achieve our 2030 delivery target. Alongside our exclusive commercialization partner ENTRA1 Energy, we are in advanced dialogue with several prospective customers across governments and industries, including data centers, utilities, coal plant operators transitioning to nuclear, and petrochemical and energy companies,&#8221; Hopkins added. 
SMR Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, NuScale Power stock was up 1.95% at $17.79 after-hours Monday.  
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45353123/quantum-stocks-are-hot-in-2025-biggest-movers-to-watch?utm_source=articleShare">Quantum Stocks Are Hot In 2025: Biggest Movers To Watch&nbsp;</a></li>
</ul>
Photo: Shutterstock

Tech

NuScale Power Reports Q1 Results: Details

Phunware (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHUN#NASDAQ">PHUN</a>) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.12) by 50 percent. This is a 45.45 percent increase over losses of $(0.33) per share from the same period last year. The company reported quarterly sales of $688.00 thousand which beat the analyst consensus estimate of $674.75 thousand by 1.96 percent. This is a 25.30 percent decrease over sales of $921.00 thousand the same period last year.

Earnings Beats

PHUN

Phunware Q1 EPS $(0.18) Misses $(0.12) Estimate, Sales $688.00K Beat $674.75K Estimate

Team (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TISI#NYSE">TISI</a>) reported quarterly losses of $(3.31) per share. This is a 0.6 percent increase over losses of $(3.33) per share from the same period last year. The company reported $198.66 million in sales this quarter. This is a 0.47 percent decrease over sales of $199.60 million the same period last year.

TISI

Team Q1 Adj. EPS $(3.31) Up From $(3.33) YoY, Sales $198.66M Down From $199.60M YoY

Life360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIF#NASDAQ">LIF</a>) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $(0.08) by 162.5 percent. This is a 135.71 percent increase over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $103.62 million which beat the analyst consensus estimate of $101.63 million by 1.96 percent. This is a 32.47 percent increase over sales of $78.23 million the same period last year.

Life360 Q1 EPS $0.05 Beats $(0.08) Estimate, Sales $103.62M Beat $101.63M Estimate

GRAL

GRAIL Partners With athenahealth To Offer Healthcare Providers Streamlined Ordering of GRAIL's Galleri Multi-Cancer Early Detection Test

East West Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWBC#NASDAQ">EWBC</a>) has outperformed the market over the past 5 years by 9.31% on an annualized basis producing an average annual return of 24.59%. Currently, East West Bancorp has a market capitalization of $13.17 billion. 
Buying $1000 In EWBC: If an investor had bought $1000 of EWBC stock 5 years ago, it would be worth $3,008.18 today based on a price of $95.57 for EWBC at the time of writing.
<h3>East West Bancorp's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747082714_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

EWBC

Here's How Much $1000 Invested In East West Bancorp 5 Years Ago Would Be Worth Today

Mobile Infrastructure (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BEEP#AMEX">BEEP</a>) affirms FY2025 sales outlook from $37.00 million-$40.00 million to $37.00 million-$40.00 million vs $38.18 million estimate.

Mobile Infrastructure Corporation Common Stock

BEEP

Mobile Infrastructure Affirms FY2025 Sales Guidance of $37.00M-$40.00M vs $38.18M Est

Pangaea Logistics Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANL#NASDAQ">PANL</a>) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.12) by 75 percent. This is a 121.43 percent decrease over earnings of $0.14 per share from the same period last year. The company reported quarterly sales of $122.80 million which missed the analyst consensus estimate of $128.45 million by 4.40 percent. This is a 17.23 percent increase over sales of $104.75 million the same period last year.

PANL

Pangaea Logistics Solns Q1 Adj. EPS $(0.03) Beats $(0.12) Estimate, Sales $122.80M Miss $128.45M Estimate

Press Releases

Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20

Indaptus Therapeutics' Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit

Legal

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments

Registration Is Now Open For Tribe Public's Webinar Event "Keys To The Kingdom: Unlocking The Power Of Your Immune System" Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Health Care

Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20

Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit

Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit

INDP

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Gr

180 Life Sciences

Azitra

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

GT Biopharma

HCW Biologics

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals

MetaVia

Mainz Biomed

PharmaCyte Biotech

Sunshine Biopharma

Soligenix

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Turnstone Biologics

Longevity Health Holdings, Inc. - Common Stock

Comments

Indaptus Therapeutics

Indaptus Therapeutics (INDP) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL